Saudi FDA launches program to accelerate rare-disease drug development
read at raps ↗RegulatoryNeutral
The Saudi Food and Drug Authority (SFDA) announced a new initiative called the New Accelerator Program for Drugs in Rare Diseases (NADR).
The program is designed to speed up the development, evaluation, and regulatory approval of medicines targeting rare conditions.
By providing a streamlined pathway, the SFDA aims to encourage investment and bring therapies to patients with unmet needs more quickly.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Asia-Pacific Roundup: Saudi FDA streamlines rare disease drug development”
read at raps ↗63 words · retrieved Aug 18
comments(0)
5-min edit window · permanent after that